These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7487421)

  • 21. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
    von Angerer E; Birnböck H; Knebel N
    Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.
    Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
    J Cancer Res Clin Oncol; 1992; 118(3):209-15. PubMed ID: 1548286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
    Gust R; Faderl M; Schönenberger H
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
    Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
    Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
    Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
    Arch Pharm (Weinheim); 2004 Jun; 337(6):335-48. PubMed ID: 15188223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative.
    Gust R; Schnurr B; Krauser R; Bernhardt G; Koch M; Schmid B; Hummel E; Schönenberger H
    J Cancer Res Clin Oncol; 1998; 124(11):585-97. PubMed ID: 9860287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and antitumor activity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)propane]dichloroplatinum(II) complexes.
    Dufrasne F; Gelbcke M; Schnurr B; Gust R
    Arch Pharm (Weinheim); 2002 May; 335(5):229-39. PubMed ID: 12210780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.
    Kim DK; Kim G; Gam J; Cho YB; Kim HT; Tai JH; Kim KH; Hong WS; Park JG
    J Med Chem; 1994 May; 37(10):1471-85. PubMed ID: 8182706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding.
    Kapp T; Dullin A; Gust R
    J Med Chem; 2006 Feb; 49(3):1182-90. PubMed ID: 16451082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Third generation antitumor platinum(II) complexes of the [1-(fluoro/difluorophenyl)-2-phenylethylenediamine]platinum(II) type.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1995; 328(7-8):595-603. PubMed ID: 7492264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New synthetic route to [bis-1,2-(aminomethyl)benzene]dichloroplatinum(II) complexes, screening for cytotoxic activity in cisplatin-sensitive and resistant human cancer cell lines, and reaction with glutathione.
    Rinke K; Grünert R; Bednarski PJ
    Pharmazie; 2001 Oct; 56(10):763-9. PubMed ID: 11683118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.
    Otto AM; Kratochwil NA; Eggers H; Bednarski PJ
    J Cancer Res Clin Oncol; 1995; 121(1):31-8. PubMed ID: 7860616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discrepancy between cytotoxicity, platinum accumulation, and DNA platination in MCF-7 breast cancer cells treated with diaqua (1,2-diphenylethylenediamine) platinum (II) sulfates and cisplatin.
    Lux F; Hollstein M; Reile H; Bernhardt G; Schönenberger H
    Biol Trace Elem Res; 1996; 53(1-3):113-28. PubMed ID: 8862742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
    Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
    J Cancer Res Clin Oncol; 1992; 118(3):201-8. PubMed ID: 1548285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of the conformational influences on the estrogenic activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes, II: Synthesis and studies on the estrogenic activity of cis- and trans[bis(2,6-dichloro-4-hydroxybenzylamine)]dihaloplatinum(II)-c omplexes.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1994 Dec; 327(12):763-9. PubMed ID: 7872853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1993 Jul; 326(7):405-13. PubMed ID: 8357303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation.
    Reile H; Bernhardt G; Koch M; Schönenberger H; Hollstein M; Lux F
    Cancer Chemother Pharmacol; 1992; 30(2):113-22. PubMed ID: 1600591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
    Knebel NG; von Angerer E
    J Med Chem; 1991 Jul; 34(7):2145-52. PubMed ID: 2066987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.